首页> 外文期刊>BMC Pulmonary Medicine >Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center
【24h】

Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center

机译:慢性呼吸系统疾病预防老年人肺炎球菌肺炎肺炎肺炎的有效性:单一中心的病例对照研究

获取原文
           

摘要

The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing pneumococcal pneumonia has been controversial. To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case–control study, including 4128 outpatients aged?≥?65?years, in the respiratory department. There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95% confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups?≥?70 and?≥?75?years, the adjusted odds ratio (95% CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12). This real-world study suggests that PPSV23 can be useful in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases.
机译:23例肺炎球菌多糖疫苗(PPSV23)在预防肺球膜炎肺炎的有效性一直存在争议。 为了评估慢性呼吸系统疾病的老年人门诊患者PPSV23的有效性,我们进行了案例对照研究,包括4128岁的门诊患者?≥?65?年,在呼吸系统。 有320名疫苗的患者,其中164例被诊断患有肺炎球菌肺炎。 调整后的差距为0.39(95%置信区间(CI),0.17至0.89)。 在年龄组组成的子集中?≥?70和≥?75?年,调整后的差距(95%CI)分别为0.16(0.04至0.67)和0.15(0.02至1.12)。 这种真实研究表明,PPSV23可用于预防老年人患有慢性呼吸系统疾病的肺炎球菌。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号